General Information of Drug Combination (ID: DCWMHN9)

Drug Combination Name
Cabazitaxel Bendamustine hydrochloride
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs Cabazitaxel   DMPAZHC Bendamustine hydrochloride   DMFH15Z
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: MCF7
Zero Interaction Potency (ZIP) Score: 1.44
Bliss Independence Score: 1.01
Loewe Additivity Score: 1.21
LHighest Single Agent (HSA) Score: 4.8

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cabazitaxel
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Metastatic prostate carcinoma N.A. Investigative [3]
Cabazitaxel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [5]
------------------------------------------------------------------------------------
Cabazitaxel Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [6]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Cabazitaxel Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Affects Expression [7]
Proline-rich AKT1 substrate 1 (AKT1S1) OT4JHN4Y AKTS1_HUMAN Decreases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of Bendamustine hydrochloride
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Approved [4]
Bendamustine hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [4]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 13 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [8]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [8]
Beta-galactosidase (GLB1) OTB0TKAG BGAL_HUMAN Increases Expression [10]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [8]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [8]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [8]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Increases Activity [8]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [8]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [11]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [8]
PRKC apoptosis WT1 regulator protein (PAWR) OTKY7W52 PAWR_HUMAN Decreases Expression [8]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Localization [8]
Death domain-associated protein 6 (DAXX) OTX6O7PL DAXX_HUMAN Decreases Expression [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Amelanotic melanoma DC2NGKO M14 Investigative [12]
Astrocytoma DC8SHCN SNB-19 Investigative [12]
Cutaneous melanoma DC3L6TL SK-MEL-28 Investigative [12]
Glioma DCE1DZK SF-539 Investigative [12]
Glioma DCDINHQ SF-295 Investigative [12]
Melanoma DCMRLFA UACC-257 Investigative [12]
Melanoma DCHXMTO MALME-3M Investigative [12]
Renal cell carcinoma DCOM78A UO-31 Investigative [12]
Invasive ductal carcinoma DC8WTQV T-47D Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
3 Cabazitaxel FDA Label
4 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
7 The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol. 2020 Aug 15;401:115091. doi: 10.1016/j.taap.2020.115091. Epub 2020 Jun 7.
8 Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
9 Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
10 Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
11 Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
12 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.